Menu Search
Equities

SenzaGen AB

26S:BER

SenzaGen AB

Actions
  • Price (EUR)0.642
  • Today's Change0.012 / 1.90%
  • Shares traded--
  • 1 Year change-9.58%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 20:43 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year SenzaGen AB grew revenues 19.39% from 41.77m to 49.87m while net income improved from a loss of 24.91m to a smaller loss of 22.10m.
Gross margin71.63%
Net profit margin-37.27%
Operating margin-37.22%
Return on assets-18.70%
Return on equity-24.07%
Return on investment-23.34%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at SenzaGen AB fell by 22.35m. Cash Flow from Financing totalled 147.00k or 0.29% of revenues. In addition the company used 16.45m for operations while cash used for investing totalled 6.08m.
Cash flow per share--
Price/Cash flow per share--
Book value per share3.11
Tangible book value per share1.44
More ▼

Balance sheet in SEKView more

SenzaGen AB uses little debt in its capital structure as supported by a debt to capital ratio of 4.43%.
Current ratio3.00
Quick ratio2.76
Total debt/total equity0.0463
Total debt/total capital0.0443
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.